AICentralResources
AI Tool Comparison

Comparing as AI Remote Patient Monitoring
Teladoc Health vs Biofourmis

Teladoc Health

Teladoc Health

VS
Biofourmis

Biofourmis

Verdict by Category

Detailed category analysis is not available for this comparison.
View Teladoc Health View Biofourmis

Detailed Comparison

Feature
Teladoc Health
Biofourmis
Pricing
CustomTeladoc Health's Integrated Care is priced through enterprise B2B contracts with employers and health plans under per-member-per-month or visit-based arrangements. Most members access Teladoc through employer benefits or health insurance at no additional out-of-pocket cost. BetterHelp direct-to-consumer therapy starts at approximately $65-$100/week billed monthly, depending on location and therapist. Insurance coverage is expanding with $90M-$105M in BetterHelp insurance revenue targeted for 2026. Hospital technology and enterprise Integrated Care require direct contract negotiation. Contact Teladoc through teladochealth.com for enterprise and employer pricing.
EnterpriseBiofourmis is an enterprise-only platform with no public pricing. All contracts are custom, negotiated directly with health systems, IDNs, hospitals, and payers. Pricing is based on patient volume, care program type (Hospital@Home, chronic disease management, post-acute care), integration requirements, and contract term. The platform is typically deployed under value-based care arrangements where costs are linked to patient outcomes and readmission reduction. Contact Biofourmis through biofourmis.com to request a demo and enterprise pricing discussion.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Summary
World's largest virtual care platform — telehealth, BetterHelp, chronic care, and Pulse AI for 100M+ members
AI remote patient monitoring with 120+ biomarkers — Hospital@Home and predictive care delivery
Teladoc Health

Teladoc Health Pros & Cons

Pros

  • World's largest virtual care company — 100M+ US members, $2.53B 2025 revenue, NYSE: TDOC
  • Broadest portfolio: urgent care, chronic care, mental health, expert opinions, and hospital tech in one platform
  • Pulse AI connects claims, devices, pharmacy, and medical records for targeted whole-person care
  • 1.27M chronic care enrollees (Q2 2026) — proven scale in diabetes and cardiometabolic management
  • BetterHelp — world's largest online therapy platform scaling insurance coverage
  • Teladoc One (July 2026) — multidisciplinary care integrating chronic, mental health, and urgent care
  • 20+ year public company track record — financial stability and enterprise credibility

Cons

  • BetterHelp revenue declining — cash-pay mental health business under pressure from insurance transition
  • Stock significantly below 2021 highs — company navigating business model shift to visit-based revenue
  • Chronic care enrollment growth slower than expected vs ambitious targets
  • Not a dedicated RPM platform — remote monitoring less specialized than Biofourmis or Current Health
  • Consumer BetterHelp and enterprise Integrated Care operate largely separately
  • Complex product portfolio can be difficult to navigate for smaller employer clients
Biofourmis

Biofourmis Pros & Cons

Pros

  • FDA 510(k) cleared + FDA Breakthrough Device Designation for BiovitalsHF — highest regulatory validation in RPM
  • $461.85M raised, $1.3B unicorn valuation — General Atlantic, CVS Health, SoftBank Vision Fund 2 backing
  • 120+ biomarker real-time analysis — most comprehensive predictive RPM analytics platform available
  • Proven clinical outcomes — reduces hospital readmissions and enables earlier intervention days before events
  • Epic EHR integration — fits natively into existing health system infrastructure without workflow disruption
  • Merged with CopilotIQ (Oct 2024) — expanded to end-to-end AI in-home care across all care stages
  • Hospital@Home validated program — one of few platforms with proven acute-care-at-home deployment at scale

Cons

  • Enterprise-only pricing — no self-service or SMB option
  • Implementation complexity — requires EHR integration and clinical workflow setup
  • No public pricing — evaluation requires direct sales engagement
  • Life sciences division divested to ActiGraph (Jan 2025)
  • Primarily US-focused deployment despite global presence
  • Not available to individual clinicians or small practices